• MegaRobo

  Participated · Series C · Jun 2022

  MegaRobo Technologies builds automation solutions for life sciences R&D, offering products that range from benchtop workflow automation to fully automated platforms for complex, large-system workflows. Its workflow automation integrates AI software, analytical instruments, hardware and consumables into a single system. The company’s products are adopted in multiple countries and are used in applications such as antibody selection, cell line development and molecular screening. MegaRobo has collaborated with partners including CELLada on high-throughput organoid cultivation and Agilent Technologies on integrated automation for synthetic biology and biopharmaceutical R&D. Led by CEO Daniel Huang, the company plans to continue investing in R&D, increase capacity and pursue global expansion. The article reports a major financing event that strengthens the company’s ability to execute on those plans. MegaRobo is a Chinese high-tech startup that applies artificial intelligence and robotics to life sciences and other sectors. The company describes itself as operating at the intersection of AI, robotics and life‑science applications. According to a company statement reported in the article, MegaRobo has raised $65 million in a funding round. The round was led by Hong Kong‑listed pharma giant WuXi AppTec, and other named participants include Matrix Partners and Sinovation. No operating metrics, valuation, or detailed use-of-proceeds were disclosed in the article. Meiga Robotics builds automated robotics and AI solutions tailored to life‑science applications including new‑drug R&D, gene engineering, and clinical diagnostics. The company has deployed dozens of automated systems and served nearly 100 life‑science customers, driving large efficiency gains: operation precision and repeatability improved by two orders of magnitude, throughput rose up to 100x in some workflows, and certain automated diagnostic workstations enabled daily nucleic‑acid testing capacity of 260,000 samples. Standard product offerings include fully automated reagent filling and dispensing systems (processing up to 900 ep tubes per hour, ~4 seconds per tube). During COVID‑19, Meiga’s automated nucleic‑acid workstations delivered ~20x throughput versus manual methods while reducing frontline infection risk. The company in 2024 launched the Meiga “Kunpeng Laboratory” sub‑brand to integrate robotics, AI and biology, and it has internally developed automated platforms for mammalian cell culture, phenotypic detection, gene editing, and high‑throughput drug screening. Meiga plans to expand its core business and continue R&D and construction of the Kunpeng Laboratory to strengthen its competitive moat in life‑science automation. The company was founded in June 2016 and is based in Beijing.

No current team members are available.